PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32955700-9	2021	CONCLUSION: Serum IL-1beta, IL-6, and IL-17A serve as indicators for predicting clinical response to celecoxib in AS patients, which may assist with the optimization of personalized treatment.	Celecoxib	101-110	interleukin 17A	Homo sapiens	38-44	
32955700-0	2021	Interleukin-1beta, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients.	Celecoxib	100-109	interleukin 17A	Homo sapiens	38-53	
23817417-6	2013	Importantly, treatment with celecoxib, a COX-2 inhibitor, resulted in significantly lower PGE2 and IL-17A, but not IFN-gamma, production.	Celecoxib	28-37	interleukin 17A	Homo sapiens	99-105